

**Appendix 6 (as supplied by the authors): Description of adverse events: Summary of any adverse events of trials included in review of anticonvulsants for low back pain ± radiating leg pain and lumbar radicular pain.**

Study	Treatment group (TG)	Placebo group (PG)	Description and frequency of adverse events (TG / PG)
<b>Atkinson 2016</b>	Gabapentin 3600 mg/d (49/55; 89.1%)	Placebo (35/53; 66.0%)	Fatigue (27 / 15), Orthostatic dizziness (24 / 14), Decreased salivation (22 / 10), Concentration difficulties (21 / 6), Increased sleep (21 / 11), Accommodation disturbance (19 / 3), Loss of balance (18 / 2), Failing memory (9 / 1), Constipation (7 / 9), Nausea/Vomiting (7 / 8), Polyuria/polydipsia (7 / 6), Reduced sleep (7 / 10), Erectile dysfunction (6 / 2), Weight gain (6 / 1), Decreased sexual desire (5 / 2), Increased dreaming (5 / 5), Tensions (5 / 1), Tension headache (3 / 2), Micturition disturbance (2 / 4), Paraesthesia (2 / 3)
<b>Baron 2010</b>	Pregabalin 600 mg/d (31/110; 28.2%)	Placebo (26/107; 24.3%)	Peripheral oedema (5 / 2), Dizziness (4 / 2), Headache (1 / 4), Weight increase (3 / 2), Somnolence (1 / 1), Fatigue (0 / 2), Dry mouth (1 / 1), Constipation (1 / 0); Serious AE: Jaundice (1 / 0), Ankle Fracture (1 / 0)
<b>Khoromi 2005 <sup>a</sup></b>	Topiramate 400 mg/d (25/29; 86.2%)	Active placebo <sup>b</sup> (21/29; 72.4%)	Paraesthesia (11 / 6), Fatigue/weakness (10 / 10), Sedation (10 / 1), Diarrhoea (9 / 3), Headache (3 / 3), Constipation (2 / 0), Depression (2 / 0), Joint pain (2 / 1), Leg cramps (2 / 5), Amnesia (1 / 0), Anorexia (0 / 1), Frequent urination (1 / 0), Thirst (1 / 0), Eyes twitching (1 / 0), Oedema (1 / 0), Speech difficulty (1 / 0), Blurred vision (1 / 0), Photophobia (1 / 0), Bleedings gums (1 / 0), Tremor (0 / 1), Somnolence (1 / 0), Extremely yellow urine (1 / 0), Decreased libido (1 / 0)
<b>Markman 2015 <sup>a</sup></b>	Pregabalin 300 mg/d (19/28; 67.9%)	Active placebo <sup>b</sup> (9/26; 34.6%)	Dizziness (12 / 1), Confusion (2 / 0) Constipation (1 / 0), Diarrhoea (3 / 2), Somnolence (5 / 2), Dry mouth (4 / 2), Nausea (3 / 4), Peripheral oedema (5 / 2), Vision changes (2 / 0), Headache (0 / 1), Frequent urination (0 / 1)
<b>Mathieson 2017</b>	Pregabalin 600 mg/d (68/106; 64.2%)	Placebo (43/101; 42.6%)	Dizziness (42 / 13), Dorsalgia (22 / 10), Sweating (11 / 15), Malaise (11 / 5), Joint disorder (5 / 0), Anxiety (5 / 4), Peripheral limb pains (4 / 6), Nausea/Vomiting (7 / 2), Disturbance of skin sensation (2 / 6), Somnolence (6 / 4), Cognitive dysfunction (8 / 2), Headache (6 / 3), Others (53 / 42); Serious AE: Hospitalisation for chest pain (0 / 1), for dyspnoea (1 / 0), for back pain (0 / 3), for psychological distress (0 / 1), Suicide attempt (0 / 1), Suicidal thoughts (1 / 0)
<b>McCleane 2000 <sup>a</sup></b>	Gabapentin 15 mg/kg/d (9/30; 30.0%)	Placebo (2/30; 6.7%)	Nausea (2 / 2), Drowsiness (2 / 0), Headaches (2 / 0), Forgetfulness (1 / 0), Constipation (1 / 0), Feeling of being "high" (1 / 0)
<b>McCleane 2001</b>	Gabapentin 1200 mg/d No data <sup>c</sup>	Placebo No data <sup>c</sup>	Nausea (6 / 5), Dizziness (5 / 0), Drowsiness (2 / 0), Loss of energy (2 / 0), Heartburn (0 / 2), Blurred vision (1 / 0), Restlessness (1 / 0), Headache (1 / 1), Disorientation (1 / 0), Skin rash (0 / 1), Constipation (0 / 1), Unpleasant dreams (0 / 1), Urinary frequency (0 / 1)
<b>Muehlbacher 2006</b>	Topiramate 300 mg/d No data <sup>c</sup>	Placebo No data <sup>c</sup>	Dizziness (5 / 3), Headache (4 / 3), Paraesthesia and/or tremor (3 / 1), Severe somnolence (2 / 0), Vision problems (2 / 1), Psychomotor slowing (2 / 1), Memory problems (2 / 1)
<b>Yildirim 2003</b>	Gabapentin 3600 mg/d (2/25; 8.0%)	Placebo (0/25; 0.0%)	Dizziness (1 / 0), Somnolence (1 / 0)

<sup>a</sup> Crossover trial  
<sup>b</sup> Active placebo = Diphenhydramine  
<sup>c</sup> Incidence of adverse events reported, but total number of participants not provided  
AE = Adverse events. TG = Treatment group. PG = Placebo group